Drug therapy: Multiple myeloma

被引：1153

作者：

Kyle, RA ^{[1
]}

Rajkumar, SV ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol & Internal Med, Rochester, MN 55905 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2004年 / 351卷 / 18期

关键词：

D O I：

10.1056/NEJMra041875

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1860 / 1873

页数：14

共 125 条

[1] Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma [J].

Abe, M ;

Hiura, K ;

Wilde, J ;

Moriyama, K ;

Hashimoto, T ;

Ozaki, S ;

Wakatsuki, S ;

Kosaka, M ;

Kido, S ;

Inoue, D ;

Matsumoto, T .

BLOOD, 2002, 100 (06) :2195-2202

[2]

Adams J, 1999, CANCER RES, V59, P2615

[3]

ALEXANIAN R, 1986, ANN INTERN MED, V105, P8, DOI 10.7326/0003-4819-105-1-8

[4] VAD-BASED REGIMENS AS PRIMARY-TREATMENT FOR MULTIPLE-MYELOMA [J].

ALEXANIAN, R ;

BARLOGIE, B ;

TUCKER, S .

AMERICAN JOURNAL OF HEMATOLOGY, 1990, 33 (02) :86-89

[5]

ALEXANIAN R, 1989, EUR J HAEMATOL, V43, P140

[6]

ALEXANIAN R, 1992, BLOOD, V80, P887

[7] The proteasome: a novel target for cancer chemotherapy [J].

Almond, JB ;

Cohen, GM .

LEUKEMIA, 2002, 16 (04) :433-443

[8] Thalidomide and dexamethasone for resistant multiple myeloma [J].

Anagnostopoulos, A ;

Weber, D ;

Rankin, K ;

Delasalle, K ;

Alexanian, R .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (05) :768-771

[9] Multiple myeloma: How far have we come? [J].

Anderson, KC .

MAYO CLINIC PROCEEDINGS, 2003, 78 (01) :15-17

[10]

[Anonymous], 2003, HEMATOL J

← 1 2 3 4 5 6 7 8 9 10 →